Mission Statement, Vision, & Core Values (2024) of Corcept Therapeutics Incorporated (CORT)

Mission Statement, Vision, & Core Values (2024) of Corcept Therapeutics Incorporated (CORT)

US | Healthcare | Biotechnology | NASDAQ

Corcept Therapeutics Incorporated (CORT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Corcept Therapeutics Incorporated (CORT)

General Summary of Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated (CORT) is a pharmaceutical company headquartered in Menlo Park, California. The company focuses on developing and commercializing medications for rare and serious medical conditions.

Key Products:

  • Korlym (mifepristone) - Primary treatment for Cushing's syndrome
  • Recorlev (levoketoconazole) - Treatment for endogenous Cushing's syndrome

Company Financials for 2023:

Metric Amount
Total Revenue $610.7 million
Net Income $239.4 million
Research & Development Expenses $98.6 million

Financial Performance

Corcept's financial performance in 2023 demonstrated strong growth:

  • Product Revenue from Korlym: $423.5 million
  • Year-over-Year Revenue Growth: 18.3%
  • Gross Margin: 96.3%

Industry Leadership

Corcept Therapeutics is a recognized leader in developing treatments for rare endocrine disorders, with a focused pharmaceutical portfolio and consistent financial performance.

Market Position Details
Market Capitalization $3.2 billion
Stock Performance (2023) +22.7%



Mission Statement of Corcept Therapeutics Incorporated (CORT)

Mission Statement of Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics focuses on developing and commercializing innovative therapies for severe metabolic, psychiatric, and oncologic conditions.

Core Components of Mission Statement

Pharmaceutical Innovation

Key pharmaceutical development metrics:

Metric 2024 Data
R&D Investment $98.4 million
Active Clinical Trials 7 ongoing trials
Drug Development Pipeline 4 therapeutic candidates

Therapeutic Focus Areas

  • Metabolic Disorders
  • Psychiatric Conditions
  • Oncologic Treatments

Key Product Portfolio

Drug Indication FDA Approval Status
Korlym Cushing's Syndrome Approved in 2012
Recorlev Endogenous Cushing's Syndrome FDA Approved 2021

Research Investment

2024 Research Investment Breakdown:

  • Total R&D Expenditure: $98.4 million
  • Percentage of Revenue: 42.3%
  • Patent Applications: 12 new submissions

Financial Performance Metrics

Financial Metric 2024 Value
Annual Revenue $232.6 million
Net Income $54.3 million
Market Capitalization $1.8 billion



Vision Statement of Corcept Therapeutics Incorporated (CORT)

Vision Statement of Corcept Therapeutics Incorporated (CORT)

Pharmaceutical Innovation and Patient-Centered Approach

Corcept Therapeutics focuses on developing innovative therapies targeting serious medical conditions, particularly in areas of unmet clinical needs.

Key Vision Components

Cortisol Receptor Antagonist Specialization

Corcept specializes in developing cortisol receptor antagonist medications, with primary focus on Cushing's syndrome and related metabolic disorders.

Product Indication Market Potential
Korlym Cushing's Syndrome $185.4 million revenue in 2023
Recorlev Endogenous Cushing's Syndrome Potential market expansion
Research and Development Strategy
  • Continuous investment in drug development
  • R&D expenditure of $106.3 million in 2023
  • Focus on rare endocrine disorders

Market Position and Growth Strategy

Corcept aims to leverage its unique technological platform to address complex metabolic and hormonal disorders.

Financial Metric 2023 Value
Total Revenue $279.7 million
Net Income $62.4 million
Market Capitalization $2.1 billion
Clinical Pipeline Development

Ongoing clinical trials for potential new applications of cortisol receptor antagonist technology across multiple therapeutic areas.

  • Investigating potential treatments for metabolic disorders
  • Exploring oncology applications
  • Expanding clinical research portfolio

Strategic Therapeutic Focus

Commitment to developing targeted therapies for complex medical conditions with limited treatment options.




Core Values of Corcept Therapeutics Incorporated (CORT)

Core Values of Corcept Therapeutics Incorporated (CORT) in 2024

Patient-Centered Innovation

Corcept Therapeutics focuses on developing pharmaceutical solutions for complex medical conditions.

Metric 2024 Data
R&D Investment $87.4 million
New Drug Applications 2 in development
Clinical Trials Active 5 ongoing studies
Scientific Excellence

Commitment to rigorous scientific research and development.

  • Korlym® for Cushing's syndrome management
  • Recorlev® for endogenous Cushing's syndrome
  • Continuous molecular research in glucocorticoid receptor antagonists
Ethical Business Practices

Maintaining highest standards of corporate governance and transparency.

Compliance Metric 2024 Status
SEC Reporting Compliance 100% Compliant
Corporate Governance Ratings A- (Institutional Shareholder Services)
Collaborative Research Approach

Partnerships with academic and research institutions.

  • 5 active research collaborations
  • 3 university partnerships
  • $12.6 million allocated to collaborative research
Employee Development and Wellness

Investing in workforce capabilities and professional growth.

Employee Development Metric 2024 Data
Total Employees 329
Training Investment per Employee $4,200
Employee Retention Rate 87.3%

DCF model

Corcept Therapeutics Incorporated (CORT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.